This is a routine 10b5-1 plan sale by an insider for tax or diversification purposes. No material signal for the stock; monitor for any deviation from the established plan pattern.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $31.46entry
- T+1 · 5mo ago +6.20%α +7.45% · $33.41
- T+5 · 5mo ago +5.50%α +7.73% · $33.19
- T+20 · 4mo ago +9.41%α +9.21% · $34.42
- T+60 · 2mo ago +19.23%α +18.23% · $37.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director and Officer Berndt Modig filed a Form 144 to sell 2,291 shares of Pharvaris N.V. common stock, valued at approximately $70,380, under a pre-existing 10b5-1 trading plan. The shares were acquired upon vesting of restricted stock units on June 11-12, 2026. This is a routine, small-dollar sale consistent with prior plan transactions and does not signal a change in insider sentiment.
Key Facts
- Insider Berndt Modig (Director and Officer) intends to sell 2,291 shares of PHVS common stock.
- Estimated aggregate market value of the proposed sale is $70,379.52.
- Shares were acquired upon vesting of restricted stock units on June 11-12, 2026.
- The sale is part of a 10b5-1 trading plan, with prior sales under the same plan in April and May 2026.
- Sale is planned for June 15, 2026 (same day as filing).
Financial Impact
Proposed sale of 2,291 shares worth approximately $70,380, representing a negligible fraction of the $2.1B market cap.
Risk Factors
- None material from this filing; the sale is small and pre-planned.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006130 |
| Document: 0001950047-26-006130-index.html | 0001950047-26-006130 |
| Document: 0001950047-26-006130.txt | 0001950047-26-006130 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers